Tenax Therapeutics Inc (TENX) Stock Analysis

AI analysis of Tenax Therapeutics Inc (TENX)

Sell

Given the current price of $1.80 and the significant downgrades from analysts, including a target reduction to $4 from $40, this stock is not a good buy right now. The company is also facing a class action lawsuit, which adds to the risk. The forward P/E ratio is extremely low at 0.299, indicating potential undervaluation, but the overall sentiment and financial performance suggest caution. The main risk is the ongoing class action lawsuit that could impact investor sentiment and stock performance.

Analyst Ratings (1)

+1433.74% upside

Buy

1 Buy

0 Hold

0 Sell

Current: 1.63

Low

20.00

Average

25.00

High

30.00

Guggenheim

Neutral

—

2026-08-31

Guggenheim

2026-08-31

Price Target

—

Neutral

Chardan

Neutral

$5

2026-08-11

Chardan

2026-08-11

Price Target

$5

Neutral

Guggenheim

Buy

$4

2026-08-11

Guggenheim

2026-08-11

Price Target

$4

Buy

Canaccord

Buy

$4

2026-08-11

Canaccord

2026-08-11

Price Target

$4

Buy

Evercore ISI

In Line

$5

2026-08-10

Evercore ISI

2026-08-10

Price Target

$5

In Line

See All Ratings

Valuation Metrics

The current forward P/E ratio for Tenax Therapeutics Inc (TENX) is 0.30, compared to its 5-year average forward P/E of -1.51.

Forward P/E

Overvalued

5Y Average P/E

-1.51

Current P/E

0.30

Overvalued

0.16

Undervalued

-3.18

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

-0.02

Current EV/EBITDA

0.00

Overvalued

0.20

Undervalued

-0.24

Forward P/S

Fair

5Y Average P/S

0.10

Current P/S

0.00

Overvalued

0.44

Undervalued

-0.24

Alphio AI Price Scenarios for TENX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%TENX

$7.01

Scenario price

B

Base

Base · 50%TENX

$6.67

Scenario price

B

Bear

Bear · 25%TENX

$6.02

Scenario price

Whales holding TENX

S

Sofinnova Investments, Inc.

+ HoldingTENX

+30.18%

3M Return

P

Perceptive Advisors LLC

+ HoldingTENX

+11.21%

3M Return

B

BVF Partners L.P.

+ HoldingTENX

+8.72%

3M Return

TENX FAQ — answered by Alphio AI

Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Given the current price of $1.80 and the significant downgrades from analysts, including a target reduction to $4 from $40, this stock is not a good buy right now. The company is also facing a class action lawsuit, which adds to the risk. The forward P/E ratio is extremely low at 0.299, indicating potential undervaluation, but the overall sentiment and financial performance suggest caution. The main risk is the ongoing class action lawsuit that could impact investor sentiment and stock performance.

1 analysts cover TENX: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 25.00.